Horizon Therapeutics PLC (HZNP)
| Market Cap | 23.09B |
| Revenue (ttm) | 2.19B |
| Net Income (ttm) | 280.04M |
| Shares Out | 224.77M |
| EPS (ttm) | 1.25 |
| PE Ratio | 80.78 |
| Forward PE | 19.80 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $101.05 |
| Previous Close | $100.07 |
| Change ($) | 0.98 |
| Change (%) | 0.98% |
| Day's Open | 100.76 |
| Day's Range | 99.88 - 103.03 |
| Day's Volume | 1,610,935 |
| 52-Week Range | 58.06 - 103.03 |
Stock Indexes Edge Higher, Sit Near All-Time Highs; CrowdStrike, Horizon Therapeutics, Global-E O.
Stock indexes edge higher, sit near all-time highs; CrowdStrike, Horizon Therapeutics, Global-E Online in focus. Investor's Business Daily has been helping people invest smarter results by providing exc...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to the 2021 Fortune Best Workplaces for Millennials™ list for the second consecutive year. Horizon...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its second-quarter 2021 financial results will be released on Wednesday, Aug. 4, 2021. Following the announcement, H...
Horizon (HZNP) starts phase II study to evaluate HZN-7734, an antibody to treat systemic lupus, which is an autoimmune disease wherein the immune system mistakenly attacks healthy cells and tissues.
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it will host a virtual R&D Day for investors and analysts on Wednesday, Sept. 29, 2021 at 8 a.m. CT. Horizon's R&D D...
If production setbacks can be avoided, gains should be in sight.
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2 trial to evaluate its development-stage medicine HZN-7734 (formerly VIB7734),...
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) and Horizon Therapeutics plc (NASDAQ: HZNP) have entered into a global collaboration and license agreement for ARO-XDH for uncontrolled gout. Horizon will pa...
PASADENA, Calif. & DUBLIN--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) and Horizon Therapeutics plc (NASDAQ: HZNP) today announced a global collaboration and license agreement for ARO...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of company information on Neuromyelitis Optica Spectrum Disorder (NMOSD) in three oral sessions during t...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has reached an agreement to purchase a drug product manufacturing facility from EirGen Pharma, an OPKO Health Com...
Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock?
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today presented new data during the EULAR European Congress of Rheumatology from the ongoing PROTECT study, which provides further insigh...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in the ADVANCE trial evaluating the concomitant use of KRYSTEXXA (pegloticase injection) w...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following upcoming conferences: Jefferies Virtual Health Care Conference Date: T...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced data presentations at the EULAR European Congress of Rheumatology, June 2 – 5, 2021. At this year's meeting, Horizon will...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to the Great Place to Work® Best Workplaces in Chicago 2021 list, ranking No. 13 in the large comp...
Here are seven biotech stocks with loads of innovation and plenty of catalysts to make money for smart investors. The post 7 Best Biotech Stocks To Buy in 2021 as Innovation Takes Center Stage appeared ...
DUBLIN--(BUSINESS WIRE)--Horizon ranked #1 in overall corporate reputation among U.S. patient groups that reported working with the company.
As the market gets back to normal, it's a great time to explore the pharma stocks that got lost in the vaccine frenzy of the past year. The post 7 of the Best Pharma Stocks to Buy Now appeared first on ...
As investors were so righteously reminded on Friday, many of the day-to-day Wall Street prognostications and strategy calls are almost always “best guesses” or data-based “assumptions.
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conference in May: Bank of America Securities 2021 Health Care Confere...
DUBLIN--(BUSINESS WIRE)--New analysis of UPLIZNA® (inebilizumab-cdon) for neuromyelitis optica spectrum disorder (NMOSD) has been published.
Horizon (HZNP) misses estimates for earnings in the first quarter of 2021 while revenues beat the same.
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that Elizabeth H.Z. Thompson, Ph.D., executive vice president, research and development, has been named a 2021 Healthcare...
Horizon Therapeutics reported a mixed quarter Wednesday, but raised its sales target for 2021. Still, HZNP stock dipped after the open.
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of -57.14% and 4.88%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Horizon Therapeutics (NASDAQ:HZNP) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share were down 92.50% year over year to $0.03, which missed the estimat...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc Reports First-Quarter 2021 Financial Results; Updating Full-Year 2021 Guidance to Incorporate Recently Acquired Viela Bio
Horizon Therapeutics (HZNP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc ranked #4 in overall corporate reputation among pharmaceutical and biotech companies.
CHARLOTTESVILLE, Va., April 21, 2021 /PRNewswire/ -- HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has identified a second drug target for the treatment of gout un...
NAARDEN, The Netherlands & MUNICH--(BUSINESS WIRE)--Forbion, a leading European life sciences venture capital firm, today announces the final close of its Forbion Growth Opportunities Fund I (“Forbion G...
Horizon Therapeutics's shares are up almost 200% over the past 12 months, buoyed by mind-boggling sales of its new blockbuster drug.
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics today announced new UPLIZNA® (inebilizumab-cdon) data being presented at the American Academy of Neurology 2021 Annual Meeting.
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced pooled data from the TEPEZZA® (teprotumumab-trbw) clinical trials are published in The Lancet Diabetes & Endocrinology.
Biotech stock Horizon Therapeutics is set up below a buy point, ahead of earnings, after soaring 102% in 2020. Can it do it again?
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its first-quarter 2021 financial results will be released on Wednesday, May 5, 2021. Following the announcement, Hor...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced the publication of data from the first randomized controlled clinical trial (RCT) of KRYSTEXXA (pegloticase injection) concomit...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announces new NMOSD data being presented at the American Academy of Neurology's 73rd Annual Meeting.
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics to resupply the market with TEPEZZA® (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED) beginning in April.
DEERFIELD, Ill.--(BUSINESS WIRE)--Horizon Therapeutics (Nasdaq: HZNP) and the Cubs today announced a Legacy Partnership that includes a Cubs STEAM Program, presented by Horizon, which will include an in...
Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock?
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a clinical trial that will evaluate a monthly dosing regimen of 16 mg of KRYSTEXXA (peg...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its strategic partner Mitsubishi Tanabe Pharma Corporation (MTPC) has received manufacturing and marketing approval ...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP), in partnership with MIT Solve, a marketplace for social impact innovation, today announced it has created a first-of-its-kind annual glo...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has completed the acquisition of Viela Bio, Inc. (Nasdaq: VIE) (“Viela”). “The Viela acquisition provides multipl...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced it ranked No. 1 on the Fortune Best Workplaces in Biopharma 2021 list. This is the fifth consecutive year Horizon has bee...
About HZNP
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI ... [Read more...]
| Industry Drug Manufacturers-General | IPO Date Jul 28, 2011 |
| Stock Exchange NASDAQ | Ticker Symbol HZNP |
Financial Performance
In 2020, HZNP's revenue was $2.20 billion, an increase of 69.26% compared to the previous year's $1.30 billion. Earnings were $389.80 million, a decrease of -31.98%.
Analyst Forecasts
According to 11 analysts, the average rating for HZNP stock is "Buy." The 12-month stock price forecast is 114.18, which is an increase of 12.99% from the latest price.